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Programmed cell death protein 1 (PD-1) and its ligand programmed cell death-ligand 1 
(PD-L1) play a vital role in suppressing the immune system and promoting self-tolerance. 
Because tumor cells are known to express PD-L1 to evade immune detection, the PD-1/PD-L1 
pathway has been the target of recent cancer therapeutic efforts. Research to date has primarily 
focused on T cells, even though the pathway has also been shown to have implications in other 
immune cells like macrophages. Recent studies have indicated that the NF-κB signaling pathway 
promotes PD-1 expression in macrophages. In this project, I aim to further elucidate how PD-1 
expression is regulated in macrophages, specifically exploring the epigenetic control of 
macrophage antitumor responses. Our lab has previously demonstrated interactions between NF-
κB family proteins and TET2 DNA demethylase. To study the possible role of TET2 in PD-1 
regulation, we used CRISPR-Cas9 to generate TET2 knockout (KO) RAW 264.7 macrophage 
cell lines. I then measured PD-1 mRNA levels in wildtype and KO cells using qRT-PCR after 
stimulation of the NF-κB pathway by lipopolysaccharide and inactivation of TET2 by the 
inhibitor itaconic acid. I found that TET2 transcriptionally promotes PD-1 expression, acting as a 
mediator between the NF-κB pathway and PD-1 expression. Understanding the mechanism of 








Programmed cell death protein 1 (PD-1) plays an essential role in balancing the 
protective effects of the immune system and self-tolerance1. PD-1 is an inhibitory receptor that is 
expressed on the surface of immune cells, and its ligand programmed cell death protein-ligand 1 
(PD-L1) is expressed by antigen presenting cells and normal tissue2. The PD-1/PD-L1 pathway 
serves to prevent the immune system from recognizing and acting against normal tissue. The 
importance of the pathway as an immune checkpoint has been demonstrated by in vivo mouse 
experiments. PD-1 knockout mice developed lupus-like autoimmune phenotypes and progressive 
arthritis, demonstrating that PD-1 is essential for the maintenance of peripheral self-tolerance3. 
Notably, the PD-1/PD-L1 pathway has been found to reduce immune responses through the 
modulation of T cell activity, specifically inducing apoptosis of antigen-specific T cells and 
preventing apoptosis of regulatory inhibitory T cells. For antigen-specific T cells, PD-1/PD-L1 
limits proliferation, downregulates effector functions and induces an exhausted phenotype, all of 
which can be reversed through the inhibition of PD-14. 
Cancer cells must evade antitumor immunity during their development and have 
commonly evolved a mechanism to take advantage of the immunosuppressive effects of the PD-
1/PD-L1. Specifically, the expression of PD-L1 by tumor cells suppresses antitumor immunity, 
as shown by mouse models in which the expression of PD-L1 by colorectal adenocarcinoma 
tumor cells inhibits T cell activity and protects PD-L1 positive cells from recognition and 
elimination5. Consequently, researchers have directed efforts towards the development of PD-
1/PD-L1 inhibitors for the treatment of various cancers. The blockade of this immune checkpoint 
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reactivates T cell responses, restoring antitumor immunity6. PD-1/PD-L1 inhibitors, specific 
monoclonal antibodies, have been effective in several clinical settings; atezolizumab for 
treatment of advanced triple-negative breast cancer, pembrolizumab for non-small cell lung 
cancer, and nivolumab for melanoma have all led to significant improvements in overall patient 
survival rates7-9.  
Characterization of the PD-1/PD-L1 pathway and its blockade in cancer therapeutics has 
largely been studied in the context of T cells; however, the pathway also has important 
implications for the function of other immune cells. Macrophages are immune cells that are 
defined by their ability to ingest and degrade dead cells, debris, and foreign materials through the 
process of phagocytosis. To carry out their function, macrophages are equipped with varying 
sensing molecules, running the risk of collateral damage precipitated by hyperactivation10. 
Because of this, immune checkpoints are important in the regulation of macrophages in both 
normal and disease contexts. Tumor-associated macrophages have been shown to express PD-1, 
with greater levels of PD-1 corresponding to lower levels of phagocytosis and, subsequently, 
greater tumor burden. The blockade of PD-1/PD-L1 promotes the antitumor efficacy of tumor-
associated macrophages11. Further investigation has specifically revealed that PD-1 expression in 
macrophages is regulated by the NF-κB pathway, which is known to play a role in inflammation. 
Inhibiting components of the NF-κB pathway leads to decreased PD-1 mRNA expression in 
macrophages, indicating NF-κB normally promotes PD-1 expression12. 
In the current study, I contribute to the discovery of a novel mechanism for the regulation 
of PD-1 expression in macrophages. Our lab has previously demonstrated that TET2 DNA 
demethylase binds to several members of the NF-κB pathway (unpublished data). Thus, I 
propose TET2, which activates gene expression through catalyzing DNA demethylation, is 
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recruited by NF-κB to regulate PD-1 expression in macrophages. To study the possible role of 
TET2 in PD-1 regulation, we generated TET2 knockout (KO) RAW 264.7 macrophage cell lines 
through the CRISPR-Cas9 system. I compared PD-1 mRNA levels by qRT-PCR in both 
wildtype (WT) and TET2 KO RAW 264.7 cells under stimulation of the NF-κB pathway by 
lipopolysaccharide (LPS) and inactivation of TET2 by itaconic acid (ITA), a direct inhibitor of 
TET2 enzymatic activity (Chen et al. submitted). Expression of IL-6, which is a cytokine known 
to be stimulated by LPS through the NF-κB pathway, and NFKBIZ, which is a member of the 
NF-κB pathway, were also compared as controls. I found that TET2 acts as a mediator between 
the NF-κB pathway and PD-1 expression, as knock-out and inhibition of TET2 resulted in 
decreased PD-1 levels even after stimulation of the NF-κB pathway. These results offer a more 
comprehensive image of immune regulation of macrophages, insight that can be utilized for the 
enhancement of current cancer immunotherapy. 
Methods: 
Generation of RAW 264.7 TET2 knockout (KO) Cell Line:  
TET2 sgRNA (Table 1) designed into a px458-cas9 plasmid backbone was used for CRISPR-
Cas9 knock-out of mouse TET2. RAW 264.7 murine macrophage cells were serum starved for 1 
hour prior to transfection using a 1μg:2µL ratio of plasmid to Promega Fugene® HD transfection 
reagent in Gibco© Opti-MEM for 3 hours. Corning© Dulbecco's Modified Eagle Medium 
(DMEM) medium with 10% fetal bovine serum (FBS) was then added to the cells, followed by 
overnight incubation at 37℃. Cells were treated with trypsin to remove them from the plate and 
filtered through a 40mL cell strainer to obtain single cells, then diluted to 2x106 cells/mL. Single 
GFP-positive cells were isolated via fluorescence-activated cell sorting (FACS). 
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RAW 264.7 Cell Culturing and Analysis:  
RAW 264.7 murine macrophage cells were cultured in Corning© Dulbecco's Modified Eagle 
Medium (DMEM) growth medium with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin antibiotics. Cell cultures were incubated in 37℃ and 5% CO2.  WT and KO cells 
were treated with 100ng/mL of LPS for 2 or 4 hours in serum free medium before harvesting. 
WT cells were pre-treated with varying concentrations of ITA for 12 hours then either treated 
with 100ng/mL of LPS or DMSO for 4 hours in medium with serum before harvesting. 
Western Blot:  
Cells were lysed using 1X Laemmli lysis buffer then heated at 100℃ for 10 minutes and 
centrifuged at 12000 rpm for 10 minutes. Samples were then analyzed on a BIO-RAD 4-15% 
precast SDS-PAGE gel and transferred onto a PVDF membrane at 100V for 1.5 hours. 
Membranes were blocked in 5% milk for 1 hour, then incubated with primary antibodies 
overnight at 4℃ and secondary antibodies for 1.5 hours at room temperature. Primary antibodies 
are listed in Table 2. Membranes were imaged using the BIO-RAD ChemiDoc MP Imaging 
system. 
Subcloning of RAW 264.7 KO Cell Lines for DNA Sequencing:  
DNA was obtained from cells by heating cell pellets suspended in distilled water at 100℃ for 10 
minutes. Polymerase chain reaction (PCR) was done using forward and reverse primers for 
mouse TET2 (Table 1). An annealing temperature of 59℃ was used. PCR products were then 
analyzed on a 1% agarose gel, and gel extraction of positive bands was performed with the 
Qiagen QIAquick® Gel Extraction Kit protocol. The Zero Blunt® TOPO® PCR Cloning Kit 
7 
was used to clone TET2 PCR products into pCR(™)-BluntII-TOPO® plasmid. Plasmids were 
then transformed into DH5α competent cells. The mixture of plasmid and competent cells were 
incubated on ice for 20 minutes, then heat-shocked for 30 seconds at 42℃. Room temperature 
S.O.C bacterial growth medium was added to the cells, and the mixtures were shaken at 37℃ for 
1 hour. Then, 100μL of the mixture was spread onto pre-warmed kanamycin LB plates to 
incubate at 37℃ overnight. For each cell line, 10 clones were picked and shaken overnight at 
37℃ in 10mL of LB medium supplemented with 50μg/ml kanamycin. Plasmids were purified 
using the Qiagen QIAprep Spin Miniprep Kit protocol, and purified plasmids were sequenced 
through Eton Bioscience, Inc using the M13R Reverse universal primer (Table 1). 
Quantitative Reverse Transcription PCR (qRT-PCR):  
Cells were lysed and RNA was purified using the Qiagen RNeasy Mini Prep Kit protocol. 
Reverse transcription PCR to obtain cDNA was performed using 1µg of purified total RNA and 
Invitrogen SuperScript® III First-Strand Synthesis System for RT-PCR. Samples were prepared 
for qPCR with 1:100 dilute sample cDNA and ThermoFisher Scientific PowerUp SYBR Green 
Master Mix. Primers used for qPCR are listed in Table 1. The reactions were performed in the 
Applied Biosystems QuantStudioTM 6 Flex Real-Time PCR System with Standard run time and 
ΔΔCT method. Measurements were obtained in triplicate.  
Co-immunoprecipitation:  
After 4 hour LPS stimulation, cells were washed two times with ice cold PBS. Cells were then 
lysed with NP-40 lysis buffer (50mM Tris-HCl buffer pH 8, 150mM NaCl, 0.1% NP-40 
detergent) supplemented with protease inhibitors and placed on a shaker for 30 minutes at 4℃. 
Lysate was collected by centrifugation at 15000 rpm, and 10 μg of antibody (Table 2) or Rabbit 
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IgG was added to the supernatant. The samples were rotated at 4℃ for 3 hours, then 20 μL of 
Protein A/G UltraLink Beads was added to each sample to rotate overnight. Beads were washed 
six times with NP-40 lysis buffer, then 1X Laemmli buffer was added.  
Table 1: Primer Sequences 
Gene Name  Primer Sequence (5’ → 3’) 
TET2 sgRNA Forward- CCTGGATATCTGTTGGCACTTT 
Primers for PCR and Sequencing 
Mouse TET2 
 




















Table 2: Antibodies 
Antibody Source (Catalog Number) Dilution 
GAPDH 
NFκB p65 (RELA) 
TET2 
TET2 (Ms specific) 
GeneTex (GTX627408) 
Cell Signaling Technology (8242S) 
Cell Signaling Technology (18950S) 













Generation and Validation of TET2 KO RAW 264.7 Cell Lines 
In order to determine the role of TET2 in macrophage PD-1 expression, our lab generated 
TET2 knockout (KO) RAW 264.7 murine macrophage cell lines through CRISPR-Cas9 (Fig. 
1A). Two previously generated KO cell lines, KO1 and KO2, were validated through both 
western blot and DNA sequencing. Using an antibody raised against mouse TET2 and a general 
TET2 antibody in western blot, TET2 was not detected in either KO1 or KO2 cells (Fig. 1B). 
DNA sequencing was used to characterize the mutations of TET2 induced by CRISPR-Cas9. 
DNA fragments encompassing the sgRNA site of cleavage were isolated from the established 
cell lines and ligated into pCR(™)-BluntII-TOPO® plasmids. Ten clones for both KO1 and KO2 
were picked and sequenced. Excluding clones that exhibited failed PCR products and 
unsuccessful insertion into plasmids, both KO1 and KO2 had two sequence variants, consistent 
with the presence of two alleles of TET2 in RAW 264.7 cells. When compared to the WT mouse 
TET2 sequence, one has a 2 base pair deletion while the other has an 8 base pair deletion. These 
results demonstrate that CRISPR-Cas9 had induced frameshift mutations in both TET2 alleles in 




Figure 1: Validation of TET2 KO RAW 264.7 cell lines 
A) Workflow to generate TET2 KO RAW 264.7 macrophage cell lines (image prepared in 
BioRender) 
B) Western blot confirmation of TET2 knockout in previously generated KO1 and KO2 cell lines  
C) DNA sequencing characterization of TET2 mutations in KO1 and KO2 (image prepared in 
SnapGene) 
Knockout of TET2 decreases PD-1 expression in macrophages after LPS stimulation 
The NF-κB signaling pathway has previously been shown to induce the expression of 
PD-1 in macrophages12. Additionally, our lab has demonstrated a physical interaction between 
TET2 and several members of the NF-κB family when TET2 was overexpressed in HEK 293T 
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cells (unpublished data). To determine if TET2 plays a role together with NF-κB in the 
regulation of PD-1 expression in macrophages, I treated both WT and TET2 KO cells with 
lipopolysaccharide (LPS), a potent activator of macrophages that induces the NF-κB pathway 
and triggers the release of pro-inflammatory cytokine IL-613. LPS stimulation was successful, as 
indicated by the similar increase of IL-6 and NFKBIZ mRNA levels in both WT and TET2 KO 
cells after 2 and 4 hours of LPS treatment relative to the untreated cells (Fig. 2A). In WT 
macrophages, LPS stimulation increased PD-1 expression levels after 2 and 4 hours of treatment 
compared to the 0h control group. In both KO1 and KO2 cells, however, there was significant 
reduction of PD-1 mRNA expression after both 2 and 4 hours of LPS stimulation compared to 
WT. Furthermore, in the TET2 KO cell lines, the basal level of PD-1 expression is decreased 




Figure 2: PD-1 expression in WT and TET2 KO macrophage cells upon stimulation of NF-κB 
pathway by LPS 
A) IL-6 (top) and NFKBIZ (bottom) mRNA expression level fold changes relative to GAPDH in 
WT and KO cell lines as positive controls for LPS stimulation. Values for WT 0h LPS 
treatment were arbitrarily set at 1. Represented data are mean+SD of three technical replicates. 
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B) PD-1 mRNA expression level fold changes relative to GAPDH in WT and KO cell lines after 
LPS stimulation. Values for WT 0h LPS treatment were arbitrarily set at 1. Represented data 
are mean+SD of three technical replicates. ***, P<0.001 when compared to WT. PD-1 
expression levels in KO cell lines are reduced by 73% from WT 0h LPS treatment, and there 
was no increase in expression upon LPS treatment. 
Inhibition of TET2 by ITA decreases PD-1 expression in macrophages after LPS stimulation 
         To further characterize the role of TET2 in PD-1 expression, I treated WT macrophages 
with a recently discovered TET2 inhibitor, itaconic acid (ITA), which has been shown by our lab 
to be a potent inhibitor of TET2 catalytic activity (Chen et al. submitted). A detailed dose course 
of ITA pre-treatment for TET2 inhibition was performed in WT cells followed by either no LPS 
treatment or 4 hours of LPS stimulation (Fig. 3). ITA did not lead to significant changes in either 
IL-6 or NFKBIZ expression levels after stimulation by LPS (Fig. 3A). In contrast, PD-1 mRNA 
levels were reduced by 75% at all concentrations of ITA in the dose course compared to the LPS 
only control. ITA treatment did not reduce expression of PD-1 in unstimulated cells; some 
concentrations exhibited increased PD-1 expression (Fig. 3B). Thus, ITA inhibits the stimulation 




Figure 3: Detailed dose course of ITA inhibition of TET2 in WT macrophage cells and the effect 
on PD-1 expression 
A) IL-6 (left) and NFKBIZ (right) mRNA expression level fold changes relative to GAPDH in 
WT cells after pre-treatment with different concentrations of ITA for 12 hours and 4 hour 
treatment of LPS. Values for LPS only treatment were arbitrarily set at 1. Represented data are 
mean+SD of three technical replicates.  
B) PD-1 mRNA expression level fold changes relative to GAPDH in WT cells after pre-treatment 
with different concentrations of ITA for 12 hours followed by 4 hour treatment of LPS (left) vs. 
no LPS treatment (right). Values for LPS only treatment were arbitrarily set at 1. Represented 
data are mean+SD of three technical replicates. For PD-1 with LPS (left), ***, P<0.001 when 
compared to LPS only treatment. PD-1 expression levels are reduced by 75% with ITA 
treatment when compared to LPS only. For PD-1 without LPS (right), *, P<0.05; **, P<0.01 
when compared to none.  
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Interaction between endogenous TET2 and RELA (p65) is undetectable in macrophage cells 
 Having established that either TET2 knock-out or TET2 inhibition decreases PD-1 
expression in the context of LPS stimulation, I wanted to explore if TET2 interacts with the 
members of the NF-κB family of proteins in macrophages, specifically if TET2 binds to RELA 
(p65), a key NF-κB pathway transcription factor. Our lab has performed co-immunoprecipitation 
and demonstrated that TET2 binds to several members of NF-κB family proteins in HEK 293T 
cells when TET2 is overexpressed (unpublished data). An endogenous Co-IP of TET2 and 
RELA was done to initially investigate if I could detect binding interactions between the two 
proteins without overexpression of either TET2 or RELA. In the IP using the TET2 antibody in 
WT cells, RELA was not detected either with or without LPS stimulation; in the IP using the 
RELA antibody, TET2 was not detected. Both proteins were present in the input positive control 
and absent in the IgG negative control. For KO1 and KO2, TET2 was predictably undetected in 
the input samples and no interactions between TET2 and RELA were detected in the IP (Fig. 5). 
These negative results are consistent with the assay not being sensitive enough to determine 





Figure 4: Immunoprecipitation of endogenous TET2 and RELA (p65) in WT and TET2 
macrophage cells 
A) Co-immunoprecipitation (Co-IP) using both TET2 and RELA antibodies for IP in WT and KO 
cells lines with and without LPS stimulation. Rabbit IgG was used as a negative control for 
target protein presence. Input represents 10% of the lysate subjected to IP. All samples were 
run on the same SDS-PAGE gel.  
 
Discussion:  
In order to elucidate the role of TET2 in the regulation of PD-1 expression in 
macrophages, we generated TET2 KO RAW 264.7 murine macrophage cell lines through 
CRISPR-Cas9 using sgRNA targeting exon 3 of TET2, which represents the N-terminal of the 
TET2 protein, to ensure that downstream transcription and translation is disrupted. Knockout of 
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TET2 was validated through both western blot and DNA sequencing. In the western blot, TET2 
was not detected in either KO1 or KO2 cells using either an antibody raised against mouse TET2 
or a general TET2 antibody (Fig. 1B). DNA sequencing further confirmed successful knockout 
of TET2 in both KO1 and KO2. Specifically, sequencing revealed two sequence variants present 
in both KO1 and KO2, one of which leads to a two base pair deletion and the other to an eight 
base pair deletion (Fig. 1C); both sequences lead to frameshift mutations that would result in 
termination of translation, preventing TET2 expression.  
A previous study found that helenalin, a selective inhibitor of RELA, and BMS-345541, a 
selective inhibitor of IκB kinase complex, significantly decreased PD-1 mRNA expression in 
macrophages after LPS stimulation, indicating NF-κB normally promotes PD-1 expression12. By 
using LPS stimulation in WT and KO macrophage cells, I was able to examine the regulatory 
role of TET2 for PD-1 expression in the context of the NF-κB pathway. KO1 and KO2 cells 
exhibited minimal PD-1 expression after 2 and 4 hours of LPS stimulation compared to WT (Fig. 
2B). The absence of TET2 diminished the inductive effects of NF-κB pathway activation. 
Inhibition of TET2 by ITA even after LPS treatment in WT macrophages returns PD-1 
expression to levels comparable to basal expression (Fig. 3B), further supporting that TET2 
regulates PD-1 expression. Altogether, TET2 has a role in transcriptionally promoting PD-1 
expression in macrophages, acting in conjunction with the NF-κB pathway.  
The absence of TET2 led to a decreased basal expression level of PD-1 in KO cells 
compared to that of WT cells (Fig. 2B), potentially suggesting that TET2 has a function in 
maintaining normal basal levels of PD-1; however, I find that inhibition of TET2 by ITA in 
unstimulated normal cells does not reduce PD-1 levels below the normal basal level (Fig. 3B). 
This indicates that TET2 does not contribute significantly to basal expression of TET2. The 
18 
knockout of TET2 could affect many pathways and transcription factors, as the cells would adapt 
to function without TET2; this could explain why KO cell lines PD-1 basal levels are reduced 
compared to WT levels. Inhibition of TET2, in contrast, results in a short term interruption of 
TET2 activity.  
The findings of this study demonstrate that TET2 is essential for the increased expression 
of PD-1 after LPS stimulation but not for basal level expression. These results are consistent with 
a mechanism where TET2 and the NF-κB pathway work together to upregulate PD-1 expression. 
TET2 does not independently bind to specific sequences of DNA; instead, TET2 relies on 
recruitment by DNA binding partners like transcription factors for targeted function14. Therefore, 
I propose that, after activation of the NF-κB pathway, RELA enters the nucleus where it binds to 
TET2 and recruits to the PD-1 promoter, leading to demethylation of PD-1 promoter and 
activation of PD-1 transcription (Fig. 5)  
In order to test the proposed mechanism, the next step will be to determine whether TET2 
directly binds with RELA in macrophages. Our lab has previously demonstrated that TET2 binds 
to several members of the NFκB family of proteins, including RelA, cRel, RelB and p50, using 
overexpression of TET2 in HEK 293T cells (unpublished data). I did not detect TET2 and RELA 
binding in an endogenous co-immunoprecipitation experiment between TET2 and RELA in 
RAW 264.7 macrophage cells (Fig. 4). A problem with this experiment was that I was not able to 
IP large enough amounts of either TET2 or RELA to detect binding of a small fraction of the 
proteins to each other. The experiment could be scaled up, or overexpression of either TET2 or 
RELA could be done to confirm that TET2 and RELA bind in macrophage cells. Also in line 
with the proposed mechanism, we intend to perform chromatin immunoprecipitation (ChIP) 
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coupled with quantitative PCR to determine whether TET2 and NF-κB are both recruited to the 
PD-1 promoter region after LPS treatment.  
Future work would also include characterizing the antitumor effects of TET2 on the 
function of macrophages, which we will address through phagocytosis assays using WT and 
TET2 KO macrophage cells. The results of this project ultimately offer a better picture of the 
immune regulation of macrophages. Discovering that TET2 is essential to the upregulation of 
PD-1 expression characterizes TET2 as a potential target for the enhancement of current 
immunotherapy, contributing to the reactivation of macrophage function to restore antitumor 
immunity. 
 
Figure 5: Proposed model for PD-1 regulation by TET2 and NF-κB RELA in macrophages after 
activation of the basal promoter 
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1) Stimulation of macrophages activates the NF-κB pathway, and RELA translocates into the 
nucleus. 
2) RELA binds to TET2 and recruits it to the PD-1 promoter. 
3) TET2 catalyzes demethylation of the PD-1 promoter, and RELA and TET2 jointly upregulate 
PD-1 expression. 
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